CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates how lung cancer cells develop resistance to targeted therapies. By understanding the mechanisms behind this tolerance, the researchers aim to combine existing drugs with new strategies to prevent cancer relapse and enhance treatment effectiveness.
Background:
A large fraction of cancer patients die because their tumors initially respond to drugs but later they evolve tolerance.
Thus, resistance to diverse drugs, along with the soaring costs of new treatments, are emerging as major societal issues of the 2020s.
Herein, we explore one of the most distressful examples, tolerance of lung cancer to EGFR-specific tyrosine kinase inhibitors (TKIs).
Working hypothesis:
In similarity to bacteria exposed to antibiotics, when cancer cells are expose…
WEIZMANN INSTITUTE OF SCIENCE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
